Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
MT newswire2026/10/08 12:0108:01 AM EDT, 10/08/2026 (MT Newswires) -- Agenus (AGEN) said Thursday that Armenia's Ministry of Health approved its combination therapy, Botvymo and Evamplix, to treat adults with a type of colorectal cancer. The company said the approvals are conditional and valid for one year, subject to renewal based on clinical updates provided to Armenian regulators. Under the approved regimen, Botvymo, or botensilimab, is given intravenously every six weeks for up to four doses, while Evamplix, or balstilimab, is given every two weeks for up to two years or until disease progression or unacceptable side effects, the company said. Agenus said it will evaluate seeking approvals in other Eurasian Economic Union countries.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
